Bristol Myers Squibb scientists in Cambridge are building the future of medicine in Boston’s backyard. This epicenter of innovation unites scientists spanning multiple functions and adds to our global network of trailblazing research and development facilities. Together, they identify and advance meaningful treatments that can transform standards of care for patients.
Bristol Myers Squibb’s state-of-the-art research and development site at Cambridge Crossing encompasses over 480,000 square feet in a 43-acre life science development. Research here expands the boundaries of science, bringing together pillars of discovery, development and data across cancer, cardiovascular, immunology and neuroscience.
Subscribe to Our Stories alerts
Beyond just relevant information about Bristol Myers Squibb's therapeutic areas and innovation, Our Stories offer a window into the work our employees do every day for patients.
The passion of hundreds of scientists in Cambridge, coupled with Bristol Myers Squibb’s broad scope of research and development capabilities around the world, has contributed to one of the most promising pipelines in the industry. Currently, that’s a diverse arsenal of 50+ compounds highlighting multiple modalities.
Every day, these dedicated scientists live and breathe molecular structure, chemistry and biology—and they collaborate to solve scientific problems as they design the next generation of molecules. “These scientists have a passion and dedication to understand what underpins human disease,” says Emma Lees, PhD, senior vice president, Head, Mechanisms of Cancer Resistance Thematic Research Center and Cambridge Site Head for BMS Cambridge. “It’s a wonderful thing to spend your life doing.”
A foundation for seamless end-to-end drug development
Dedication to breakthrough discoveries and solutions means equal dedication to new paths of research. A multi-disciplinary, collaborative, translational approach empowers that kind of thinking. From mechanisms of cancer resistance to clinical pharmacology, scientists in Cambridge collaborate closely with small molecule drug discovery and biotherapeutics teams to develop new treatments. These teams attack disease with a continually expanding range of drug modalities, including innovative small molecules.
Scientific discovery and transformational outcomes cannot happen without a shared vision. For these teams, the possibilities of the future guide what they do today. They imagine what medicine could look like, they explore the opportunities and they create transformational medicines that will shape the next decade and beyond for people living with serious diseases.
Focusing on interdisciplinary translational medicine illuminates the best approaches — whether those might be monotherapies or combinations of therapies — to both refine and define current standards of care. A precision approach uncovers the right pathways and targets for specific patient populations, integrating these insights with appropriate modalities, combinations and sequencing. This leads to maximum therapeutic benefit for patients with serious diseases and a transformational pipeline of promising molecules, first-in-class treatments and best-in-class medicines.
In Cambridge, several disciplines focus on translational research, seamlessly connecting with the thematic research centers to develop potential new medicines for the clinic. Other translational scientists track the effects and doses of new molecules, measuring everything against the original scientific hypothesis. Together with pathologists, translational scientists also look at that patient response to identify the best doses and combinations for registrational trials.
By combining human genetics knowledge, artificial intelligence and machine learning, Bristol Myers Squibb’s scientists are able to back-translate its industry-leading clinical and translational datasets.
The Informatics and Predictive Sciences group at Cambridge partners with discovery scientists to better understand the human causal nature of different diseases to improve ongoing research efforts, inform future hypotheses and fuel the next way of discovery. The resulting insights help design better clinical trials, enable quick decisions and increase the probability of success for new medicines in late-stage research.
Collaboration as a catalyst for sustainable communities
Bristol Myers Squibb’s culture of inclusion has cultivated an agile and responsive work environment. Diverse experiences and perspectives drive scientific breakthroughs and transformative results.
Innovation extends beyond the walls of Bristol Myers Squibb where biopharma, academic and clinical partnerships fuel earlier discovery and development.
Bristol Myers Squibb’s vision for transforming patients’ lives through science goes beyond the lab and into the community. Community giving, grant-making programs and engagement activities support Massachusetts in the areas of STEM education, health and wellness and human service.
A partnership with Boston Healthcare for the Homeless provides access to comprehensive healthcare. Other collaborations with co-ops, STEM outreach programs and workforce development initiatives open doors to people from communities underrepresented in life sciences. Currently, that includes organizations such as Science Club for Girls, MassBioEd and the Museum of Science.
From leading academic institutions to high school STEM programs, hospital systems to grassroots care organizations, Bristol Myers Squibb has embedded itself in the fabric of Cambridge’s life science community. At the center of this innovation ecosystem is the belief that the future of medicine is created and sustained by strong, inclusive, diverse and equitable communities – locally nurtured and globally connected.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work.